| Project/Area Number |
23591872
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
ZHENG Yun-Wen 横浜市立大学, 医学部, 助教 (80404995)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
谷口 英樹 横浜市立大学, 医学(系)研究科(研究院), 教授 (70292555)
武部 貴則 横浜市立大学, 医学部, 准教授 (20612625)
|
|---|
| Research Collaborator |
TANIGUCHI Hideki 横浜市立大学, 医学研究科, 教授 (70292555)
TAKABE Takanori 横浜市立大学, 医学部, 准教授 (20612625)
KOZAWA Mayumi 横浜市立大学, 医学研究科, 大学院生
GUAN Hong-bin 横浜市立大学, 医学研究科, 大学院生
KONDO Akihisa 横浜市立大学, 医学研究科, 大学院生
OTA Mitsuyoshi 横浜市立大学, 市民総合医療センター, 准教授 (60315794)
TATSUMI Kenji 横浜市立大学, 医学部, 助教 (80567628)
ISHIKAWA Yasushi 横浜市立大学, 医学研究科, 准教授 (70254208)
ENDO Itaru 横浜市立大学, 医学研究科, 教授 (60211091)
OSHIMA Takashi 横浜市立大学, 市民総合医療センター, 准教授 (10448665)
FUJII Shoichi 横浜市立大学, 市民総合医療センター, 准教授 (70326065)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | CD44variant2 / 予後予測因子 / 大腸癌 / 癌幹細胞 / CD133 / CD44 variant 2 / がん幹細胞 / 消化器癌 / CD44バリアント / 大腸がん / フローサイトメトリー |
|---|
| Research Abstract |
CD133 and CD44 are putative cancer stem cell markers in colorectal cancer (CRC). However, their clinical significance is currently unclear. In this study, we evaluated primary CRC cell to determine the significance of several cancer stem cell markers, including CD133 and CD44, as predictors of tumourigenesis and prognosis. We fund that CD44+, CD133+ and CD133+CD44+ sub-populations were significantly more tumourigenic than the total cell population. The clinical samples expressed several transcript variants of CD44. Variant 2 was specifically overexpressed in both primary tumours and xenografts in comparison with the normal mucosa. A prognostic assay using qRT-PCR showed that the CD44v2high group had a significantly worse prognosis than the CD44v2low group.
In conlusion, CD44 is an important CSC marker in CRC patients. And the CRC patients with high expression of CD44v2 have a poorer prognosis than patients with other CD44 variants.
|
